Related Experiment Videos
Thiazolidinediones in dermatology
1Department of Medicine (Dermatology), Vanderbilt University, Nashville, TN, USA. alan.boyd@vanderbilt.edu
International Journal of Dermatology
|June 7, 2007
Summary
Thiazolidinediones (glitazones) improve glycemic control in type II diabetes by activating PPAR-gamma. These drugs also show promise for various skin conditions due to their anti-inflammatory and cell-normalizing effects.
Area of Science:
- Pharmacology
- Endocrinology
- Dermatology
Background:
- Thiazolidinediones (glitazones) are a class of drugs for type II diabetes.
- They target the peroxisome proliferator-activated receptor gamma (PPAR-γ).
Purpose of the Study:
- To summarize the mechanisms and diverse clinical applications of thiazolidinediones.
- Highlight their role in glycemic control and potential dermatological benefits.
Main Methods:
- Review of thiazolidinedione's mechanism of action at the molecular level.
- Analysis of clinical outcomes in diabetes and various skin conditions.
Main Results:
- Glitazones activate PPAR-γ, leading to enhanced insulin sensitivity and glucose uptake.
- Demonstrated efficacy in treating psoriasis, lipodystrophy, and necrobiosis lipoidica.
- Showed anti-inflammatory effects, including reduction of tumor necrosis factor alpha.
Conclusions:
- Thiazolidinediones are effective for type II diabetes management.
- Their anti-inflammatory and cell-normalizing properties offer therapeutic potential for specific dermatological conditions.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:17Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...